ReviewVaccines2017
Neutralization of Human Cytomegalovirus Entry into Fibroblasts and Epithelial Cells.
Review in Vaccines, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Characterization of humoral and cellular immunologic responses to an mRNA-based human cytomegalovirus vaccine from a phase 1 trial of healthy adults.Journal of virology · 2024Article
- Nonhuman primate models of pediatric viral diseases.Frontiers in cellular and infection microbiology · 2024Review
- Potential of Anti-CMV Immunoglobulin Cytotect CPMicroorganisms · 2022Article
- Antibody Titers Against Human Cytomegalovirus gM/gN and gB Among Pregnant Women and Their Infants.Frontiers in pediatrics · 2022Article
- A Novel Strain-Specific Neutralizing Epitope on Glycoprotein H of Human Cytomegalovirus.Journal of virology · 2021Article
- Selection of Human Cytomegalovirus Mutants with Resistance against PDGFRα-Derived Entry Inhibitors.Viruses · 2021Article
- Rat and human cytomegalovirus ORF116 encodes a virion envelope glycoprotein required for infectivity.Virology · 2021Article
- Prefusion structure of human cytomegalovirus glycoprotein B and structural basis for membrane fusion.Science advances · 2021Article
- Repertoire characterization and validation of gB-specific human IgGs directly cloned from humanized mice vaccinated with dendritic cells and protected against HCMV.PLoS pathogens · 2020Article
- Modeling Human Cytomegalovirus-Induced Microcephaly in Human iPSC-Derived Brain Organoids.Cell reports. Medicine · 2020Article
- Evasion of a Human Cytomegalovirus Entry Inhibitor with Potent Cysteine Reactivity Is Concomitant with the Utilization of a Heparan Sulfate Proteoglycan-Independent Route of Entry.Journal of virology · 2020Article
- Neutralizing Monoclonal Antibodies Reduce Human Cytomegalovirus Infection and Spread in Developing Placentas.Vaccines · 2019Article
- The Humoral Immune Response Against the gB Vaccine: Lessons Learnt from Protection in Solid Organ Transplantation.Vaccines · 2019Review
- CD46 facilitates entry and dissemination of human cytomegalovirus.Nature communications · 2019Article
- Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.Journal of virology · 2018Article
- Cytomegalovirus: Shape-Shifting the Immune System.Journal of immunology (Baltimore, Md. : 1950) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Human cytomegalovirus (HCMV) is a leading cause of permanent birth defects, highlighting the need to develop an HCMV vaccine candidate. However, HCMV vaccine development is complicated by the varying capacity of neutralizing antibodies (NAb) to interfere in vitro with the HCMV entry routes mediating infection of fibroblast (FB) and epithelial cells (EC). While HCMV infection of FB and EC requires glycoprotein complexes composed of gB and gH/gL/gO, EC infection depends additionally on the envelope pentamer complex (PC) composed of gH, gL, UL128, UL130 and UL131A. Unlike NAb to gB or gH epitopes that can interfere with both FB and EC infection, NAb targeting predominantly conformational epitopes of the UL128/130/131A subunits are unable to prevent FB entry, though they are highly potent in blocking EC infection. Despite the selective requirement of the PC for EC entry, the PC is exceptionally immunogenic as vaccine antigen to stimulate both EC- and FB-specific NAb responses due to its capacity to elicit NAb that target epitopes of the UL128/130/131A subunits and gH. These findings suggest that the PC could be sufficient in a subunit vaccine formulation to induce robust FB- and EC-specific NAb responses. In this short review, we discuss NAb responses induced through natural infection and vaccination that interfere in vitro with HCMV infection of FB and EC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.